The SELECT Trial has revealed the potential of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in combating kidney function decline among individuals with overweight or obesity and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results